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OBJECTIVES The goal of this study was to determine if restenosis is increased in mild and moderate chronic
kidney disease (CKD) patients after percutaneous coronary intervention (PCI).
BACKGROUND Mortality is increased in CKD after PCI. Restenosis may contribute to increased late
mortality.
METHODS We analyzed 11,187 patients with a creatinine 1.8 mg/dl from the Prevention of
REStenosis with Tranilast and its Outcomes (PRESTO) trial, grouped by estimated
creatinine clearance (CrCl) (60, 60 to 89, 89 ml/min). The Cox proportional hazards
models investigated the association between CrCl group and death, myocardial infarction,
and target vessel revascularization (TVR). Generalized estimating equation regression models
determined the association between CrCl group and lesion-specific restenosis.
RESULTS At 30 days, there was no difference in myocardial infarction, death, or TVR between the CrCl
groups. At nine months, mortality was higher in the lowest CrCl group (2.2%, 1.2%, 0.8%;
p  0.001), which was no longer significant after adjusting for confounding variables.
Myocardial infarction and TVR were not different between the groups. In patients
undergoing protocol follow-up angiography, restenosis (50%) was not increased with CKD
(32%, 32%, 37%; p  0.02).
CONCLUSIONS Mortality nine months after PCI is mildly increased in mild or moderate CKD patients.
However, restenosis is not and does not account for the increased mortality. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.052Cardiol 2004;44:1786–91) © 2004 by the American College of Cardiology Foundation
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lild chronic kidney disease (CKD) is associated with lower
rocedural success and increased in-hospital complications
fter percutaneous coronary intervention (PCI) (1). Even if the
CI procedure is successful, cardiovascular events and mortal-
ty are increased up to 50% compared with patients having
ormal renal function (2). The cause of the increased mortality
s unknown, but could relate to increased restenosis or accel-
rated atherosclerosis progression elsewhere in the coronary
irculation. No studies in the current era evaluated both clinical
nd angiographic restenosis in mild and moderate CKD
atients. Thus, this prospectively defined substudy of the
revention of REStenosis with Tranilast and its Outcomes
PRESTO) trial was designed to address this issue.
ETHODS
atient population. In the PRESTO trial, 11,484 patients
ere enrolled from 432 centers after successful PCI of 1
essel (3,4). Patients were excluded if a myocardial infarc-
ion (MI) occurred 48 h, if the PCI was staged, if a prior
From the *Mayo Clinic, Rochester, Minnesota; †Duke University, Durham, North
arolina; ‡University of Texas School of Public Health, Houston, Texas; §William
eaumont Hospital, Royal Oak, Michigan; University of Texas Medical School and
exas Heart Institute, Houston, Texas; and ¶GlaxoSmithKline, Collegeville,
ennsylvania. This study was supported by grants from GlaxoSmithKline Pharma-
euticals.v
Manuscript received February 20, 2004; revised manuscript received July 6, 2004,
ccepted July 12, 2004.CI was 3 months, if the creatinine was 1.8 mg/dl, if
nemia or chronic liver disease was present, or if creatinine
as not available at study entry (n  297). This analysis
ncluded all remaining 11,187 patients.
andomization and treatment. Patients were randomly
ssigned to one of five parallel groups including placebo or
ranilast. Because tranilast did not affect any outcome
easured (death, MI, restenosis, and target vessel revascu-
arization [TVR]), regardless of renal function, patients
rom all groups were analyzed together (4).
reatinine clearance. Creatinine clearance (CrCl) was
stimated using the Cockroft-Gault formula (5). Patients
ere divided into three CrCl groups: 89 ml/min, 60 to 89
l/min, and 60 ml/min.
ollow-up. Clinical follow-up occurred at one, three, and
ine months. A prespecified subgroup of patients under-
ent nine-month angiographic follow-up or sooner if indi-
ated. Complete revascularization was defined as no re-
aining stenosis70% by visual analysis and restenosis was
efined as a luminal diameter stenosis 50% at follow-up
n a per-lesion basis.
nd points. The primary end points for this analysis were
VR and restenosis at nine-month follow-up. Target vessel
evascularization was defined as repeat PCI or coronary
rtery bypass graft (CABG) surgery performed for revascu-
arization of a stenosis in the vessel originally treated. Target
essel revascularization-free survival time was measured in
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November 2, 2004:1786–91 Renal Dysfunction and Restenosisays from the date of randomization to the date of TVR or
ast known date the patient was known to be alive without
aving a TVR. Patients known to be TVR-free were
ensored. For nine-month TVR, event-free survival time
as truncated at 270 days; for 30-day TVR event-free
urvival was truncated at this time point. Secondary end
oints include the composite of death/MI/TVR as well as
eath and MI individually.
tatistical methods. Hazard ratios (HRs) for outcomes
ere estimated using the Cox proportional hazards models
omparing the mild and moderate CKD groups with the
ormal group. Adjusted HRs were estimated after including
otential confounding variables in the model, demonstrat-
ng a statistically significant association with the specific
utcome using a stepwise variable selection procedure. The
KD variables, age, and gender were forced into all of the
ox models.
In order to account for multiple treated lesions per
Abbreviations and Acronyms
CABG  coronary artery bypass graft
CHF  congestive heart failure
CKD  chronic kidney disease
CrCl  creatinine clearance
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous coronary intervention
PRESTO  Prevention of REStenosis with Tranilast
and its Outcomes trial
TVR  target vessel revascularization
Table 1. Baseline Patient Characteristics
Characteristic
<60
(n  1,749)
Height (m) 1.67  0.1
Weight (kg) 72.9  12.7
Age (yrs) 68.9  9.1
Male (%) 61
Diabetes mellitus (%) 27
Taking insulin (%) 7
Taking oral agents (%) 13
Hypertension (%) 71
Hyperlipidemia (%) 62
Statin use (%) 68
Current smoking history (%) 14
Prior PCI (%) 34
Prior CABG (%) 18
Prior MI (%) 42
Prior angina (%) 69
History of CHF (%) 11
Peripheral vascular disease (%) 10
Indications for PCI (%)
Unstable angina 57
Stable angina 43
Glycoprotein IIb/IIIa use (%) 37
*p Value between all three CrCl groups.
CABG  coronary artery bypass graft; CHF  congestive he
infarction; PCI  percutaneous coronary intervention.atient, generalized estimating equation regression models
ere developed to assess the association between CKD
roups and restenosis at nine-month follow-up using the
AS procedure GENMOD (SAS Institute Inc., Cary,
orth Carolina). An exchangeable correlation matrix for
he multiple lesions was specified, which assumes a constant
orrelation among all pairs of lesions within an individual.
dds ratios were estimated comparing the CKD groups
ith the normal group. Adjusted odds ratios were estimated
fter including other covariates significantly associated with
estenosis in the multivariable model.
Data are presented as the mean value  1 standard
eviation for continuous variables and percentages for di-
hotomous variables. All analyses were performed using
AS software (SAS Institute Inc.). Comparisons between
roups for patient-specific variables were made with the
ne-way analysis of variance, chi-square test, or log-rank
est. All tests of significance were two-tailed. Lesion-
pecific characteristics were compared across groups using
eneralized estimating equations and repeated measures
nalysis of variance for categorical and continuous variables,
espectively.
ESULTS
aseline patient characteristics. The baseline patient
haracteristics are shown in Table 1. Frequency of tranilast
reatment was not different between CrCl groups (80%, p
.92).
ngiographic characteristics. The lowest CrCl group had
greater number of diseased coronary vessels than the
CrCl (ml/min)
p Value*
60–89
(n  4,054)
>89
(n  5,384)
1.70 0.1 1.74 0.1 0.001
79.1 12.7 89.7 16.0 0.001
63.2 9.0 55.2 9.0 0.001
77 83 0.001
22 24 0.001
5 6 0.81
12 13 0.042
60 59 0.001
64 67 0.001
72 76 0.001
19 28 0.001
31 30 0.005
15 11 0.001
38 39 0.010
65 64 0.001
6 5 0.001
6 5 0.001
0.001
51 52
49 48
33 39 0.001art failure; CrCl  creatinine clearance; MI  myocardial
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Renal Dysfunction and Restenosis November 2, 2004:1786–91igher CrCl groups, but had a similar number of vessels
reated (Table 2). Stents were used in 75% of the lesions in
he lowest CrCl group, 76% in the middle group, and 78%
n the highest CrCl group (p  0.003). Patients in the
owest CrCl group more frequently had calcified (19%, 17%,
3%; p  0.001), restenotic (15%, 13%, 13%; p  0.039),
nd tortuous lesions (9%, 7%, 7%; p  0.032). The lowest
rCl group less commonly had bifurcation lesions (10%,
1%, 12%; p  0.09) and total occlusions treated (5%, 6%,
%; p  0.001). Angiographic follow-up was lowest in the
owest CrCl group (67%, 70%, 74%; p  0.004). The
ngiographic lesion characteristics (Table 3) demonstrate
hat the highest CrCl group had a greater pretreatment
esion stenosis.
linical and angiographic outcomes. At 30 days, there
ere no differences in death, MI, repeat revascularization,
r need for CABG surgery between the renal function
roups (Table 4). However, at nine-month follow-up (mean
49 days), mortality was nearly three times greater in the
Table 2. Angiographic Characteristics
Characteristic
<60
(n  434
Ejection fraction (%) 60.5 13
Number of diseased vessels (mean) 1.9  0.8
One (%) 38
Two (%) 35
Three (%) 27
Number of vessels treated (mean) 1.1  0.3
One (%) 86
Two (%) 14
Three (%) 0.2
Maximum inflation pressure (atm) 13.7 3.5
Average length of the stent (mm) 16.5  5.7
*p Value between all three CrCl groups.
CrCl  creatinine clearance.
Table 3. Angiographic Lesion Characteristics
Characteristics per Lesion
<60
(n  563
Lesion classification (%)
A 21
B1 36
B2 34
C 9
Lesion length (mm) 12.3 6.8
Reference diameter (mm) 2.9 0.6
MLD (mm) 0.8 0.4
Pre-stenosis (%) 75.6 14
Acute gain (mm) 1.8  0.7
After stenosis (%) 10.6 12
MLD immediately after PCI (mm) 2.70 0.6
Complete revascularization (%) 22
Dissection (after PCI), % 5*p Value between all three CrCl groups.
CrCl  creatinine clearance; MLD  minimal lumen diameteowest CrCl group (2.2%) than the highest CrCl group
0.8%). There were no differences between the CrCl groups
n frequency of MI, PCI, CABG surgery, or TVR. More-
ver, after protocol-driven follow-up angiography (n 
,556), restenosis was not increased with CKD (32%, 32%,
7%; p  0.02) and actually highest in the highest CrCl
roup (Table 5).
Using a Cox proportional hazards model, the risk of
eath at nine months was lower in the highest CrCl group
ompared with the lowest CrCl group (Table 6). There was
o difference in the risk of MI or TVR. When the Cox
roportional hazards model was adjusted for age, gender,
iabetes, hypertension, smoking status, prior CABG sur-
ery, peripheral vascular disease, congestive heart failure,
nd unstable angina, the risk of death was no longer
ifferent between the CrCl groups (Table 7). Additionally,
n the angiographic substudy of 2,556 successfully treated
esions, after adjustment, creatinine was not independently
ssociated with a higher frequency of restenosis as was
CrCl (ml/min)
p Value*
60–89
(n  997)
>89
(n  1345)
62.1  13.7 60.2  11.7 0.030
1.9  0.8 1.8  0.8 0.12
39 42
37 35
24 23
0.29
1.2  0.4 1.2  0.4 0.23
82 87
17 13
0.4 0.5
0.49
13.3  3.7 13.6  3.6 0.022
16.3  5.5 16.5  5.5 0.58
CrCl (ml/min)
p Value*
60–89
(n  1,315)
>89
(n  1,784)
19 20 0.92
41 38
32 37
8 6
11.6  6.0 12.4  6.6 0.002
2.9  0.6 2.9  0.6 0.34
0.9  0.5 0.8  0.5 0.44
76.0  14.0 78.1  14.2 0.001
1.8  0.7 1.9  0.7 0.001
10.3  11.8 9.3  12.0 0.04
2.66  0.61 2.73  0.64 0.06
24 30 0.001
4 4 0.59)
.7)
.3
.0
5r; PCI  percutaneous coronary intervention.
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November 2, 2004:1786–91 Renal Dysfunction and Restenosisypothesized and was actually associated with a lower risk of
estenosis (Table 5).
nteraction with diabetes. All follow-up outcomes were
nalyzed across diabetics and non-diabetics, respectively.
he interaction terms between CrCl groups and diabetes
ere not significant for any of the outcomes: follow-up
tenosis50% (p 0.37), death (p 0.52), MI (p 0.72),
VR (p  0.95), and death/MI/TVR (p  0.98). These
esults suggest that the effect of CrCl group on outcome
oes not differ between diabetics and non-diabetics.
nteraction with stenting. All follow-up outcomes were
nalyzed across stenting and non-stenting groups, respec-
ively. The interaction terms between CrCl groups and stent
se were not significant for any of the outcomes: follow-up
tenosis50% (p 0.16), death (p 0.91), MI (p 0.44),
VR (p  0.83), and death/MI/TVR (p  0.92). These
esults suggest the effect of CrCl group on outcome does not
iffer between those receiving stents and those not receiving
tents.
able 5. Lesion-Specific Angiographic Follow-Up at 9 Months A
Characteristic
<
(n 
eference diameter (mm) 2.8 
hange in reference diameter from baseline (mm) 0.1
estenotic lesions (%) 3
uminal stenosis (%) 38.0
ate loss in MLD (mm) 0.9 
dds ratio, follow-up stenosis 50% (95% CI) 0.79 (0.
djusted odds ratio, follow-up stenosis 50% (95% CI) 0.62 (0.
Table 4. Adverse Clinical Outcomes at 30 Day
Event, %
<60
(n  1,749)
Subsequent events (30 days)
Death 0.17
MI 0.69
Death/MI 0.74
PCI 1.89
CABG surgery 0.17
Revascularization (any) 2.00
TVR 1.26
Death/MI/TVR 1.66
Subsequent events (9 months)
Death 2.16
MI 1.49
Death/MI 3.37
PCI 15.32
CABG surgery 3.95
Revascularization (any) 18.47
TVR 14.41
Death/MI/TVR 16.58
*p Value between all three CrCl groups.
TVR  target vessel revascularization; other abbreviationp Value between all three CrCl groups.
CrCl  creatinine clearance; CI  confidence interval; MLD  minimal luminal diamISCUSSION
n this, the largest PCI restenosis study ever reported, we
ound that patients with mild or moderate CKD, restenosis,
nd TVR are not increased after PCI in the current stenting
ra. Myocardial infarctions were not increased during the
ine months after PCI in CKD patients. The lowest CrCl
roup had a 2.7-fold increased risk of death within nine
onths compared with the highest CrCl group. However,
fter adjusting for other variables, CrCl group was no longer
ndependently associated with mortality.
KD and mortality. Cardiovascular events are 3.5 to 100
imes greater in dialysis-dependent CKD patients than the
eneral population (6,7). Recently, we and others (2,8)
emonstrated that mild CKD is associated with a doubling
f mortality. The degree of CKD appears to be directly
roportional to the risk for cardiovascular events and mor-
ality. The current study demonstrates that the risk of death
t nine months in the lowest CrCl group was 2.7 times
PCI
CrCl (ml/min)
p Value*
60–89
(n  927)
>89
(n  1,331)
2.8  0.5 2.9  0.5 0.09
0.1  0.3 0.0  0.3 0.37
32 37 0.02
9 37.4 27.8 39.9  29.3 0.017
0.9  0.8 1.0  0.8 0.09
01) 0.79 (0.66–0.95) 1.00 0.02
87) 0.78 (0.62–0.97) 1.00 0.01
d 9 Months After PCI
CrCl (ml/min)
p Value*
60–89
(n  4,054)
>89
(n  5,384)
0.27 0.07 0.06
0.39 0.46 0.33
0.59 0.54 0.62
1.38 1.28 0.17
0.07 0.15 0.50
1.43 1.43 0.20
0.81 0.97 0.28
1.23 1.17 0.28
1.16 0.80 0.001
1.41 1.34 0.89
2.39 2.08 0.009
14.11 14.43 0.48
3.90 4.10 0.87
16.92 17.61 0.35
13.37 14.49 0.27
14.45 15.40 0.16
Table 1.fter
60
371)
0.5
0.3
2
27.
0.8
61–1.
45–0.s aneter.
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Renal Dysfunction and Restenosis November 2, 2004:1786–91reater than the highest CrCl group, and there was an
ntermediate risk of 1.5 in the middle CrCl group.
Possible explanations for the increased mortality associ-
ted with mild CKD include increased classic cardiovascular
isk factors in these patients, accelerated atherogenesis, and
ncreased complications from cardiovascular disease when it
evelops. Not surprisingly, CKD patients have increased
ge, diabetes, and hypertension compared with those with
ormal renal function (2,8). In PRESTO, patients with
KD were older, with a greater frequency of diabetes and
ypertension. The lowest CrCl group also had more prior
CI and CABG surgery. Remarkably, despite this increased
isk profile of the CKD population, there was lower use of
tatin therapy. Moreover, the lowest CrCl group had lower
omplete revascularization than the highest CrCl group
22% vs. 30%), which is another risk for subsequent cardio-
ascular events and mortality. Unlike previous studies, in the
RESTO trial, CKD was no longer independently associ-
ted with mortality after adjusting for the other variables.
his difference may be due to the shorter follow-up of nine
onths in our study compared with previous studies or
reater adjustment for covariates in our study. Because
KD is associated with a lower frequency of success and a
reater complication rate during PCI, the difference in our
tudy may in part be due to the fact that patients were
nrolled in the PRESTO trial only if the PCI procedure had
een successful. Moreover, because of the homogenous
ature of trial participants owing to strict inclusion and
xclusion criteria, these patients may differ from the general
opulation.
KD and MIs. Nearly one-half of the deaths in the
ialysis-dependent CKD population are caused by cardio-
ascular disease (9). Patients with CKD not only have a
Table 6. Cox Proportional Hazards Models fo
Outcome
<60
(n  1,749)
HR (95% CI)
Death 2.69 (1.73–4.17)
MI 1.12 (0.72–1.76)
TVR 1.01 (0.88–1.17)
Death, MI, or TVR 1.10 (0.96–1.26)
*p Value between all three CrCl groups.
HR  hazard ratio; other abbreviations as in Tables 1 an
Table 7. Adjusted Cox Proportional Hazards M
Outcome
<60
(n  1,749)
HR (95% CI)
Death 1.16 (0.68–1.96)
MI 1.06 (0.63–1.77)
TVR 1.01 (0.86–1.19)
Death, MI, or TVR 1.04 (0.89–1.21)*p Value between all three CrCl groups.
Abbreviations as in Tables 1, 4, and 6.uch greater frequency of MIs, but also have a higher
ortality from MIs (10,11). Among those receiving dialysis,
he mortality is nearly 60% in the first year after a first MI.
n-hospital mortality after a MI is 2% with normal renal
unction, 6% with mild CKD, 14% with moderate CKD,
1% with severe CKD, and 30% in dialysis patients (11).
espite the high risk of death in CKD patients with a MI,
roven therapies for treatment, including reperfusion ther-
py, beta-blockers, and aspirin, are all underutilized (11,12).
In the PRESTO trial, there was no such association
etween CKD and MI in the nine months after successful
CI. Myocardial infarction frequency was only 1.5% in the
owest CrCl group, compared with 1.3% in the highest
rCl group. The most likely explanation for the difference
n our study compared with previous studies is a shorter
ollow-up period. However, other factors such as less
ultivessel disease, the exclusion of patients with a creati-
ine 1.8 mg/dl, and the requirement for enrollment after
successful PCI procedure may have contributed.
KD and restenosis. Enthusiasm for performing PCI in
atients with severe CKD has been limited by the results of
tudies with balloon angioplasty alone, which demonstrated
ignificantly lower procedural success rates and markedly
igher restenosis rates, as high as 81% (13–15). As in the
eneral population, stenting improves procedural success
nd reduces clinical cardiovascular events in end-stage CKD
atients by one-half at one year (16). Conflicting results
xist regarding the frequency of restenosis in CKD patients
eceiving stents; some studies demonstrated that TVR was
ot higher in this population (17), whereas others still found
doubling of the TVR in CKD patients (35% vs. 16%, p 
.05) (18). However, repeat angiography was not performed
fter PCI in any of these studies.
th, MI, and TVR
(ml/min)
p Value*
0–89
4,054)
(95% CI)
>89
(n  5,384)
HR (95% CI)
0.96–2.20) 1.00 0.01
0.74–1.49) 1.00 0.87
0.82–1.02) 1.00 0.25
0.84–1.04) 1.00 0.07
ls for Death, MI, and TVR
(ml/min)
p Value*
60–89
 4,054)
(95% CI)
>89
(n  5,384)
HR (95% CI)
(0.66–1.60) 1.00 0.84
(0.75–1.58) 1.00 0.90
(0.85–1.08) 1.00 0.70
(0.85–1.07) 1.00 0.43r Dea
CrCl
6
(n 
HR
1.46 (
1.05 (
0.92 (
0.94 (ode
CrCl
(n
HR
1.03
1.09
0.96
0.95
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November 2, 2004:1786–91 Renal Dysfunction and RestenosisUnderstanding the impact of mild CKD on restenosis is
mportant because mild CKD is more than 10 times more
revalent than end-stage CKD and affects approximately
% of the population (19). Previous database studies showed
hat mild CKD is not associated with increased TVR (2,20).
ecause these studies did not prospectively perform
ollow-up angiography, it is unknown whether silent reste-
osis is increased, accounting for the higher mortality in this
opulation, as seen in diabetic patients. Our study demon-
trates not only that there was no increased risk of TVR
ssociated with mild or moderate CKD, but also demon-
trates for the first time that angiographic restenosis is also
ot increased. Thus, in the stenting era, PCI appears to have
he same favorable results in this population as in those with
ormal renal function.
tudy limitations. The Cockroft-Gault formula was used
o estimate CrCl, which is a reliable but surrogate assess-
ent of renal function. The mild inaccuracies of this
ethod introduced into the study should not significantly
lter the interaction of renal function and restenosis, in part
ecause of the large patient population studied. Addition-
lly, because of the exclusion criteria of the PRESTO trial,
nly patients with a creatinine 1.8 mg/dl were included in
he study. Thus, few patients with severe CKD were
valuated and the results of this study cannot be applied to
atients with more severe CKD. Lastly and perhaps most
mportantly, this was a study of patients in whom PCI was
uccessful, not of patients undergoing PCI. Because success
ates are lower and complications are higher in CKD,
aution must be taken when comparing these results with
hose from other studies.
onclusions. After successful PCI, mortality is increased
n patients with mild or moderate CKD over a nine-month
ollow-up period, although the association is no longer
ignificant after adjustment for other risk factors known to
e associated with mortality. There is no increased risk of
I or TVR among CKD patients at nine months. Further-
ore, angiographic restenosis was not increased in CKD
atients, demonstrating that the increased mortality among
KD patients is not due to silent restenosis. These data
uggest that PCI is associated with similar outcomes in
atients with mild or moderate CKD as in those without
KD.
eprint requests and correspondence: Dr. Patricia J. M. Best,
ayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.-mail: best.patiricia@mayo.edu.EFERENCES
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